Alzheimer's Disease Psychosis
Neurology
3
Pipeline Programs
1
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Acadia PharmaceuticalsSAN DIEGO, CA
3 programs1
1
1
ACP-204Phase 31 trial
ACP-204Phase 2/31 trial
Pimavanserin tartratePhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
Acadia PharmaceuticalsACP-204
Acadia PharmaceuticalsACP-204
Acadia PharmaceuticalsPimavanserin tartrate
Clinical Trials (3)
Total enrollment: 2,007 patients across 3 trials
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Start: Apr 2024Est. completion: May 2029752 patients
Phase 3Enrolling By Invitation
ACP-204 in Adults With Alzheimer's Disease Psychosis
Start: Nov 2023Est. completion: Feb 20281,074 patients
Phase 2/3Recruiting
A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis
Start: Nov 2013Est. completion: Oct 2016181 patients
Phase 2Completed
Related Jobs in Neurology
Director, Distribution & Services
Xenon Pharmaceuticals
Remote
10h ago
Senior Medical Science Liaison (NYC Tri-State)
Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr
Director of Medical Affairs
CoMind
Miami, FL
10h ago
Director of Finance
CoMind
London, UK
10h ago
Electronics Engineering Manager
CoMind
London, UK
10h ago
Director of Information Technology
Zavation Medical Products
10h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 2,007 patients
1 companies competing in this space